Internal Medicine, Medical Oncology · Fort Myers, FL
NPI
1518156959
Since 2007
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
14543 Global Pkwy Ste 1102nd
Fort Myers, FL, 33913
Phone (239) 264-7026
Groups this clinician bills Medicare through
Medicare paid, 2024
$433K
18,587 services
Medicare patients, 2024
282
Average age 73
Drug cost, 2024
$7.5M
2,260 prescriptions
Company payments, 2025
$3,186
From 44 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Venkata K Parsa was code 85025 (blood count), 280 times for 141 patients. In total Venkata K Parsa billed 18,587 services in 76 codes, and Medicare paid $433K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-04-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 85025 Blood Count | Office | 280 | 141 | $7.61 | $2,131 |
| 99214 Office E&M - Established | Office | 225 | 111 | $102.27 | $23K |
| 36415 Venipuncture Blood Collection | Office | 156 | 82 | $8.65 | $1,349 |
| 80053 Clinical Chemistry | Office | 102 | 73 | $10.35 | $1,056 |
| M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 76 | 32 | $69.76 | $5,302 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 55 | 45 | $13.18 | $725 |
| 96413 Chemotherapy Administration | Office | 53 | 18 | $102.48 | $5,431 |
| 96375 Injection Administration | Office | 52 | 13 | $12.19 | $634 |
| 99232 Hospital E&M - Subsequent | Facility | 49 | 34 | $63.18 | $3,096 |
| 96372 Injection Administration | Office | 38 | 19 | $11.41 | $434 |
| 99222 Hospital E&M - Initial | Facility | 37 | 37 | $105.63 | $3,908 |
| 99223 Hospital E&M - Initial | Facility | 29 | 29 | $133.40 | $3,868 |
| 99204 Office E&M - New | Office | 24 | 24 | $130.07 | $3,122 |
| 83615 Clinical Chemistry | Office | 24 | 18 | $5.92 | $142 |
By year: 2022 $146K for 1,813 services; 2023 $15K for 456 services; 2024 $433K for 18,587 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 280 | 141 | $7.61 | $2,131 |
| 36415 Venipuncture Blood Collection | 156 | 82 | $8.65 | $1,349 |
| 80053 Clinical Chemistry | 102 | 73 | $10.35 | $1,056 |
| 83615 Clinical Chemistry | 24 | 18 | $5.92 | $142 |
Medicare prescription drug claims, 2024
In 2024, the drug Venkata K Parsa prescribed most often to Medicare patients was Tamoxifen Citrate, with 97 prescriptions and refills. In total Venkata K Parsa wrote 2,260 Medicare prescriptions that cost $7.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamoxifen Citrate Generic | 97 | 253 | 33 | $2,435 |
| Oxycodone Hcl Generic | 85 | 85 | 32 | $1,127 |
| Letrozole Generic | 80 | 237 | 28 | $2,041 |
| Morphine Sulfate Er Morphine Sulfate | 65 | 65 | 19 | $1,484 |
| Dexamethasone Generic | 64 | 76 | 37 | $1,433 |
| Eliquis Apixaban | 63 | 87 | 17 | $49K |
| Anastrozole Generic | 62 | 186 | 25 | $1,256 |
| Potassium Chloride Generic | 59 | 114 | 22 | $712 |
| Revlimid Lenalidomide | 56 | 56 | 17 | $1.2M |
| Prochlorperazine Maleate Generic | 53 | 53 | 39 | $709 |
| Alprazolam Generic | 49 | 52 | 17 | $109 |
| Ondansetron Hcl Generic | 49 | 49 | 35 | $688 |
| Lenalidomide Generic | 45 | 45 | 12 | $691K |
| Methylprednisolone Generic | 39 | 39 | 27 | $256 |
| Furosemide Generic | 36 | 80 | 15 | $121 |
Brand drugs: - claims; generic drugs: 1,702 claims; opioid claims: 242.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Venkata K Parsa $3,186 ($3,186 in general payments such as food, travel and fees) from 44 companies. The largest payer was Pfizer Inc. with $556.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 23 | $556 |
| AstraZeneca Pharmaceuticals LP AZN | 12 | $265 |
| Daiichi Sankyo Inc. 4568.T | 10 | $207 |
| Merck Sharp & Dohme LLC MRK | 8 | $194 |
| GlaxoSmithKline, LLC. GSK | 9 | $157 |
| Novartis Pharmaceuticals Corporation NVS | 6 | $133 |
| Celgene Corporation BMY | 5 | $113 |
| Gilead Sciences, Inc. GILD | 4 | $105 |
| Janssen Biotech, Inc. JNJ | 6 | $104 |
| Genzyme Corporation SNY | 5 | $96.46 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.